Primary Product
AbBu Therapy - A novel drug to prolong life after injury & blood loss
Future Users
Military Medics, Ambulances, Hospitals, Surgeons, Strategic Stockpiles
Stage & Sector
Early-Stage Biotech w/ Proof of Concept in Small Animal Studies
Our Focus
Lead Optimization of AbBu Therapy, an antibody designed to neutralize the Shock Toxin
About Us
Shock Biotech was founded by trauma surgeon Dr. Donald S. Gann to advance a discovery made in his lab for a new hemorrhagic shock treatment called AbBu Therapy.
Shock Biotech was founded with proof of concept data and a mission to advance AbBu Therapy to patients.
What is Shock?
The Definition
Our body’s stress response to blood loss (hemorrhage).
The Causes
Car Crashes, Gun Shot Wounds, Burns, & Military Casualties.
The Symptoms
Low blood pressure & high potassium; commonly fatal.
The Impact
Injury is the #1 Cause of Death People Ages 1 - 44 in the United States
The Future
We Believe in a Better Future for Patients in Shock
Shock Therapeutics Biotech Believes in a Future Where...
You are administered AbBu Therapy at the scene of injury to allow for more time to get to a hospital before shock kills you.
AbBu Therapy keeps you alive long enough for trauma surgeons to stop the bleeding and repair your injuries.
You can survive shock, giving you the opportunity to recover from an otherwise fatal injury & return home to your family.
The Market
Circulatory Shock is a Global Problem
Hemorrhagic Shock
4M
People Killed Globally by Trauma Associated with Injury & Violence
World Health Organization
Septic Shock
11M
People Killed Globally by Viral & Bacterial Infections Turned Septic
Rudd et al 2020
Cardiogenic Shock
14M
People Killed Globally by Cardiac Insults Including Heart Attacks and Strokes
World Health Organization
World Health Organization
The Team
Founder in Memoriam
Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.
Donald S.
Gann MD
Susan
Gann Hibbs
Chief Executive Officer
Corporate Vision
Investor Relations
Corporate Operations
Lewis C.
Hibbs III
Chief Operating Officer
R&D Operations
Antibody Engineering
Research & Writing
Les E.
Johnson
Chief Technology Officer
Global Drug Development
Regulatory Lead
Quality & Risk Management
The Story
